These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 33727311)

  • 1. Evolution of Brain Volume Loss Rates in Early Stages of Multiple Sclerosis.
    Uher T; Krasensky J; Malpas C; Bergsland N; Dwyer MG; Kubala Havrdova E; Vaneckova M; Horakova D; Zivadinov R; Kalincik T
    Neurol Neuroimmunol Neuroinflamm; 2021 May; 8(3):. PubMed ID: 33727311
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessing Biological and Methodological Aspects of Brain Volume Loss in Multiple Sclerosis.
    Andorra M; Nakamura K; Lampert EJ; Pulido-Valdeolivas I; Zubizarreta I; Llufriu S; Martinez-Heras E; Sola-Valls N; Sepulveda M; Tercero-Uribe A; Blanco Y; Saiz A; Villoslada P; Martinez-Lapiscina EH
    JAMA Neurol; 2018 Oct; 75(10):1246-1255. PubMed ID: 29971335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brain volume change after high-dose immunosuppression and autologous hematopoietic cell transplantation for relapsing-remitting multiple sclerosis.
    Lee H; Nakamura K; Narayanan S; Brown RA; Nash RA; Griffith LM; Steinmiller KC; Devine SM; Hutton GJ; Popat U; Racke MK; Georges GE; Bowen JD; Arnold DL
    Mult Scler Relat Disord; 2021 Sep; 54():103149. PubMed ID: 34284316
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Role of High-Frequency MRI Monitoring in the Detection of Brain Atrophy in Multiple Sclerosis.
    Uher T; Krasensky J; Sobisek L; Seidl Z; Bergsland N; Dwyer MG; Kubala Havrdova E; Zivadinov R; Horakova D; Vaneckova M
    J Neuroimaging; 2018 May; 28(3):328-337. PubMed ID: 29485230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deep gray matter volume loss drives disability worsening in multiple sclerosis.
    Eshaghi A; Prados F; Brownlee WJ; Altmann DR; Tur C; Cardoso MJ; De Angelis F; van de Pavert SH; Cawley N; De Stefano N; Stromillo ML; Battaglini M; Ruggieri S; Gasperini C; Filippi M; Rocca MA; Rovira A; Sastre-Garriga J; Vrenken H; Leurs CE; Killestein J; Pirpamer L; Enzinger C; Ourselin S; Wheeler-Kingshott CAMG; Chard D; Thompson AJ; Alexander DC; Barkhof F; Ciccarelli O;
    Ann Neurol; 2018 Feb; 83(2):210-222. PubMed ID: 29331092
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Age-dependent cut-offs for pathological deep gray matter and thalamic volume loss using Jacobian integration.
    Opfer R; Krüger J; Spies L; Hamann M; Wicki CA; Kitzler HH; Gocke C; Silva D; Schippling S
    Neuroimage Clin; 2020; 28():102478. PubMed ID: 33269702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Within-patient fluctuation of brain volume estimates from short-term repeated MRI measurements using SIENA/FSL.
    Opfer R; Ostwaldt AC; Walker-Egger C; Manogaran P; Sormani MP; De Stefano N; Schippling S
    J Neurol; 2018 May; 265(5):1158-1165. PubMed ID: 29549466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient and neurologist preferences in the UK for relapsing-remitting multiple sclerosis treatments: findings from a discrete choice experiment.
    Tencer T; Will O; Kumar J; Cambron-Mellott MJ; Mackie DS; Beusterien K
    Curr Med Res Opin; 2021 Sep; 37(9):1589-1598. PubMed ID: 34129418
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Grey matter atrophy is associated with disability increase in natalizumab-treated patients.
    Ciampi E; Pareto D; Sastre-Garriga J; Vidal-Jordana A; Tur C; Río J; Tintoré M; Auger C; Rovira A; Montalban X
    Mult Scler; 2017 Apr; 23(4):556-566. PubMed ID: 27354019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A 6-year clinical and MRI follow-up study of patients with relapsing-remitting multiple sclerosis treated with Interferon-beta.
    Paolillo A; Pozzilli C; Giugni E; Tomassini V; Gasperini C; Fiorelli M; Mainero C; Horsfield M; Galgani S; Bastianello S; Buttinelli C
    Eur J Neurol; 2002 Nov; 9(6):645-55. PubMed ID: 12453081
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brain volume loss in multiple sclerosis is independent of disease activity and might be prevented by early disease-modifying therapy.
    Slezáková D; Kadlic P; Jezberová M; Boleková V; Valkovič P; Minar M
    Neurol Neurochir Pol; 2023; 57(3):282-288. PubMed ID: 37144903
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evolution of different MRI measures in patients with active relapsing-remitting multiple sclerosis over 2 and 5 years: a case-control study.
    Horakova D; Cox JL; Havrdova E; Hussein S; Dolezal O; Cookfair D; Dwyer MG; Seidl Z; Bergsland N; Vaneckova M; Zivadinov R
    J Neurol Neurosurg Psychiatry; 2008 Apr; 79(4):407-14. PubMed ID: 17550987
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation between brain volume loss and clinical and MRI outcomes in multiple sclerosis.
    Radue EW; Barkhof F; Kappos L; Sprenger T; Häring DA; de Vera A; von Rosenstiel P; Bright JR; Francis G; Cohen JA
    Neurology; 2015 Feb; 84(8):784-93. PubMed ID: 25632085
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis.
    Fisniku LK; Brex PA; Altmann DR; Miszkiel KA; Benton CE; Lanyon R; Thompson AJ; Miller DH
    Brain; 2008 Mar; 131(Pt 3):808-17. PubMed ID: 18234696
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progression in disability and regional grey matter atrophy in relapsing-remitting multiple sclerosis.
    Hofstetter L; Naegelin Y; Filli L; Kuster P; Traud S; Smieskova R; Mueller-Lenke N; Kappos L; Gass A; Sprenger T; Penner IK; Nichols TE; Vrenken H; Barkhof F; Polman C; Radue EW; Borgwardt SJ; Bendfeldt K
    Mult Scler; 2014 Feb; 20(2):202-13. PubMed ID: 23804554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gray matter atrophy correlates with MS disability progression measured with MSFC but not EDSS.
    Rudick RA; Lee JC; Nakamura K; Fisher E
    J Neurol Sci; 2009 Jul; 282(1-2):106-11. PubMed ID: 19100997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Brain volume loss is present in Japanese multiple sclerosis patients with no evidence of disease activity.
    Yokote H; Kamata T; Toru S; Sanjo N; Yokota T
    Neurol Sci; 2018 Oct; 39(10):1713-1716. PubMed ID: 29974307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brain atrophy as a non-response predictor to interferon-beta in relapsing-remitting multiple sclerosis.
    Rojas JI; Patrucco L; Miguez J; Besada C; Cristiano E
    Neurol Res; 2014 Jul; 36(7):615-8. PubMed ID: 24620963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A regional consensus recommendation on brain atrophy as an outcome measure in multiple sclerosis.
    Alroughani R; Deleu D; El Salem K; Al-Hashel J; Alexander KJ; Abdelrazek MA; Aljishi A; Alkhaboori J; Al Azri F; Al Zadjali N; Hbahbih M; Sokrab TE; Said M; Rovira À
    BMC Neurol; 2016 Nov; 16(1):240. PubMed ID: 27881095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The relationship between the rate of brain volume loss during first 24 months and disability progression over 24 and 48 months in relapsing MS.
    Jeffery DR; Di Cantogno EV; Ritter S; Meier DP; Radue EW; Camu W
    J Neurol; 2016 Feb; 263(2):299-305. PubMed ID: 26568562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.